Drug-eluting stent in preventing in-stent restenosis in the role and clinical application of.docVIP

 PAGE \* MERGEFORMAT 8 Drug-eluting stent in preventing in-stent restenosis in the role and clinical application of [Abstract] coronary stent implantation in the treatment of coronary heart disease has become a kind of an important means to a definite effect, but the very high (10% ~ 50%) of in-stent restenosis rate limiting stent implantation development. Which can slow the release of partial inhibition of vascular endothelial and smooth muscle proliferation of drugs, drug-eluting stent (DES) applications, significantly reducing in-stent restenosis rate, significantly prolonged the stent re-percutaneous coronary intervention time. Currently there are clinical application of rapamycin-eluting stent DES and paclitaxel-eluting stents, which significantly reduces in-stent restenosis rate effect has more and more have been completed or ongoing clinical trials confirmed. [Keywords:] stent; drug-eluting; Restenosis 1987 stents in clinical practice in the application is percutaneous coronary intervention (percutanenous coronary intervention, PCI) in the field of a milestone in more than 10 subsequent years, coronary stent implantation as coronary heart disease (coronary heart disease, CHD) are the exact effect of a treatment of an important means, but quite high (10% ~ 50%) of in-stent restenosis (in.stent restenosis, ISR) limits the rate of stent implantation development. As can be slow-release partial inhibition of vascular endothelial and smooth muscle proliferation of drugs, drug-eluting stent (drug.eluting stent, DES) application, ISR rate was reduced significantly prolonged the line again after stenting PCI time. 1 DES to reduce in-stent restenosis mechanism Restenosis after PCI main mechanisms: (1) the balloon inflation led to partial vessel wall injury triggered neointima (neointimal, NI) hyperplasia; (2) immediately after balloon deflation from the blood vessel elasticity retraction; (3) lead to vascular remodeling in the late diameter loss; (4) thrombos